- Home
- RCMT vs BIOA Comparison
RCMT vs BIOA Comparison
Compare RCMT & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCMT
- BIOA
- Stock Information
- Founded
- RCMT 1971
- BIOA 2015
- Country
- RCMT United States
- BIOA United States
- Employees
- RCMT N/A
- BIOA N/A
- Industry
- RCMT Professional Services
- BIOA Biotechnology: Pharmaceutical Preparations
- Sector
- RCMT Consumer Discretionary
- BIOA Health Care
- Exchange
- RCMT Nasdaq
- BIOA Nasdaq
- Market Cap
- RCMT 133.5M
- BIOA 139.8M
- IPO Year
- RCMT N/A
- BIOA 2024
- Fundamental
- Price
- RCMT $22.14
- BIOA $4.34
- Analyst Decision
- RCMT Strong Buy
- BIOA Hold
- Analyst Count
- RCMT 2
- BIOA 4
- Target Price
- RCMT $33.50
- BIOA $5.67
- AVG Volume (30 Days)
- RCMT 33.1K
- BIOA 348.2K
- Earning Date
- RCMT 08-06-2025
- BIOA 08-15-2025
- Dividend Yield
- RCMT N/A
- BIOA N/A
- EPS Growth
- RCMT N/A
- BIOA N/A
- EPS
- RCMT 1.74
- BIOA N/A
- Revenue
- RCMT $290,914,000.00
- BIOA $1,451,000.00
- Revenue This Year
- RCMT $16.29
- BIOA N/A
- Revenue Next Year
- RCMT $6.16
- BIOA N/A
- P/E Ratio
- RCMT $13.10
- BIOA N/A
- Revenue Growth
- RCMT 8.53
- BIOA N/A
- 52 Week Low
- RCMT $13.18
- BIOA $2.88
- 52 Week High
- RCMT $26.37
- BIOA $26.62
- Technical
- Relative Strength Index (RSI)
- RCMT 50.52
- BIOA N/A
- Support Level
- RCMT $22.02
- BIOA N/A
- Resistance Level
- RCMT $23.15
- BIOA N/A
- Average True Range (ATR)
- RCMT 0.67
- BIOA 0.00
- MACD
- RCMT -0.24
- BIOA 0.00
- Stochastic Oscillator
- RCMT 7.72
- BIOA 0.00
About RCMT RCM Technologies Inc.
RCM Technologies Inc is a provider of business and technology solutions designed to enhance and maximize the operational performance of its customers. It operates in three segments: Specialty Health Care, Engineering, and Life Sciences, Data and Solutions (LS&D). The company generates maximum revenue from the Specialty Health Care segment that provides staffing solutions including medical healthcare professionals, health information management professionals, nurses, paraprofessionals, physicians, and therapists. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Puerto Rico, the Philippines, and Europe.
About BIOA BioAge Labs Inc. Common Stock
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.